By Josh White
Date: Tuesday 03 Feb 2026
(Sharecast News) - Merck & Co reported better-than-expected fourth-quarter results on Tuesday, driven by continued strength in its oncology franchise and animal health division, but shares slipped after the drugmaker issued a 2026 outlook that fell short of market expectations as it braced for patent expiries and generic competition.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 115.84 |
| Change Today | $ 2.47 |
| % Change | 2.18 % |
| 52 Week High | $118.46 |
| 52 Week Low | $73.47 |
| Volume | 25,793,563 |
| Shares Issued | 2,527.64m |
| Market Cap | $292,802m |
| RiskGrade | 92 |
| Strong Buy | 8 |
| Buy | 10 |
| Neutral | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 15:57 | 194 @ $116.11 |
| 15:57 | 100 @ $116.10 |
| 15:56 | 100 @ $116.13 |
| 15:56 | 131 @ $116.12 |
| 15:56 | 141 @ $116.12 |
You are here: research